Clinical trials: Insulin
Diabetes Mellitus, Type 1
Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.
The purpose of the proposed study is to compare insulin Degludec [TRESIBA® (insulin degludec injection)] with insulin Glargine U100 [Lantus® (insulin glargine injection)] to determine the basal insulin of choice for adults with…
- Trial name
- SafrTravlT1D (NCT03668808)
- Testing
- Insulin Degludec, Insulin Glargine, TRESIBA® FLEXTOUCH®
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Sansum Diabetes Research Institute
Diabetes Mellitus
Integration of Continuous Glucose Monitoring Into a BiHormonal Closed-Loop Artificial Pancreas
The investigators hypothesize that our closed-loop glucose-control system can provide BG control in subjects with type 1 diabetes using the estimated BG signal from a CGM as the input signal to the controller.
- Trial name
- CL2 (NCT01161862)
- Testing
- Bi-hormonal (insulin and glucagon) artificial pancreas
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Boston University Charles River Campus
Hepatic Steatosis, Bariatric Surgery Candidate
Hepatic Mitochondrial Function in Youth
Assess the impact of bariatric surgery on hepatic energy metabolism and glucose and insulin dynamics in obese youth
- Conditions
- Hepatic Steatosis, Bariatric Surgery Candidate, Adolescent Obesity, Obesity
- Trial name
- MANGO (NCT03587727)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Obesity, Insulin Resistance
Correction of Vitamin D Levels and Its Effect on Insulin Resistance and Weight Gain in Obese Youth
Vitamin D deficiency is extremely common in obese youth. In our obese population followed in the Endocrinology clinic at Children's Medical Center Dallas, vitamin D levels were inversely correlated with a measure of insulin…
- Conditions
- Obesity, Insulin Resistance, Vitamin D Deficiency
- Trial name
- NCT02168660
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Perrin C White, MD
Diabetes
Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital
In this study the investigators would like to test the hypothesis that in diabetic patients discharged from the hospital, SoloSTAR Glargine insulin will be superior to syringe-injected Glargine in terms of diabetes control…
- Trial name
- NCT01203774
- Testing
- Glargine insulin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus
Aldosterone and Glucose Homeostasis
Determine the effect of aldosterone on how the body handles glucose (sugar).
- Trial name
- NCT00732160
- Testing
- Aldosterone infusion (A), Vehicle Infusion (V), High Sodium Diet (HS)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Vanderbilt University
Hepatitis C, Chronic, Hepatitis C Virus
Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)
Naïve patients with chronic hepatitis C (CHC) of any genotype will be treated with a standard treatment regimen (pegylated interferon and ribavirin) according to routine clinical practice in Russia.
- Trial name
- NCT00705224
- Testing
- Pegylated Interferon, Ribavirin
- Volunteers
- 250 people
- Sponsor
- Merck Sharp & Dohme LLC
Contraception
Synthetic vs Natural Estrogen in Combined Oral Contraception
The main objective of the study is to compare the metabolic effects of natural estradiol and synthetic ethinylestradiol used in combined oral contraception in healthy women.
- Trial name
- SYLVI (NCT02352090)
- Testing
- Ethinyl estradiol / dienogest, Estradiol valerate / dienogest, Dienogest
- Where
- 2 sites in Finland
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Acromegaly
Effects of Sandostatin LAR® in Acromegaly
This study aims primarily to determine the effect Insulin-like Growth Factor 1 (IGF-1) normalization into current IGF-I normal ranges with Sandostatin LAR® therapy on biochemical metabolic, cardiovascular and body composition…
- Trial name
- NCT01424241
- Testing
- Sandostatin LAR
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Columbia University
Type 1 Diabetes
EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes
Diabetes is increasingly common among youth, forecasting early complications. Type 1 (T1D) cause early heart disease, shortening lifespan despite modern improvements in control of blood sugars and other risk factors for heart…
- Trial name
- EMERALD (NCT01808690)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Colorado, Denver
Non Insulin Dependent Diabetes, Pregnancy
Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes
Many women come into pregnancy with diabetes that is controlled with either Metformin or diet control; however, the current standard of care for the treatment of preexisting diabetes in pregnancy is insulin.
- Trial name
- MIPOD (NCT00835861)
- Testing
- Metformin, Insulin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of North Carolina, Chapel Hill
Diabetes Mellitus, Type 2
ADAM17 and Vascular Function in Diabetes
The objective of this project is to determine the extent to which administration of the dietary supplement phosphatidylserine (PS), a competitive inhibitor of ADAM17 sheddase activity, effects vascular function and…
- Trial name
- ADAM17 (NCT04557228)
- Testing
- Phosphatidylserine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Missouri-Columbia
Mild Cognitive Impairment, Cognitive Impairment
SNIFF Multi-Device Study 2
The SNIFF Device study will involve using one of three devices to administer insulin through each participant's nose or intra-nasally, accompanied by a lumbar puncture.
- Trial name
- NCT04199767
- Testing
- 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company), 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Non-alcoholic Fatty Liver Disease
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
The aim of study was to evaluate the effect of helicobacter pylori eradication on liver fat content, liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass…
- Trial name
- NCT01712711
- Testing
- H.pylori eradication
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Tehran University of Medical Sciences
Diabetes Mellitus, Type 2, Newly Diagnosed
Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients
The purpose of this study is to investigate and evaluate the effects of different interventions (1. exenatide, 2. insulin, 3. thiazolidinedione) on glycemic control and β-cell function in newly diagnosed drug-naïve type 2…
- Trial name
- NCT01147627
- Testing
- exenatide injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R, Pioglitazone
- Where
- 25 sites in China
- Volunteers
- 416 people
- Sponsor
- Sun Yat-sen University
Type 1 Diabetes Mellitus
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
This Phase 3 study was intended to demonstrate superiority of either Sotagliflozin high dose or low dose versus placebo on glycosylated hemoglobin A1C (A1C) reduction at Week 24 when used as an adjunct in adult participants with…
- Trial name
- inTandem2 (NCT02421510)
- Testing
- Sotagliflozin
- Where
- 96 sites in Austria, Belgium and 15 more
- Volunteers
- 782 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus, Type 1
Improving Diabetes in Emerging Adulthood
This project will test the efficacy of a multi-component behavioral intervention to improve metabolic control among older adolescents and emerging adults (16-21) with T1D, a group with chronic poor metabolic control.
- Trial name
- IDEA (NCT04066959)
- Testing
- Motivational Enhancement System (MES), Question Prompt List (QPL), Text Message Reminders (TXT)
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Wayne State University
Acute, Non-traumatic Subarachnoid Hemorrhage, Intraparenchymal Hemorrhage
Normoglycemia and Neurological Outcome
Brain injury patients who meet defined criteria will be assigned to intensive insulin treatment (target blood glucose levels of 10-110 mg/dl) or conventional IV insulin treatment (target glucose of 150-170 mg/dl).
- Conditions
- Acute, Non-traumatic Subarachnoid Hemorrhage, Intraparenchymal Hemorrhage, Brain Injuries
- Trial name
- NCT01137773
- Testing
- Insulin, Conventional insulin treatment
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Louisville
Type 1 Diabetes, Hypoglycemia
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents
Objective: to gain experience in children and younger adolescents with in-home use of an algorithm that will dose insulin to minimize projected hyperglycemia overnight in addition to suspending the pump if hypoglycemia is…
- Conditions
- Type 1 Diabetes, Hypoglycemia, Hyperglycemia, Artificial Pancreas
- Trial name
- PHM3 (NCT02714972)
- Testing
- Hyperglycemia Minimization Algorithm
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Jaeb Center for Health Research
Diabetes Mellitus, Type 2
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control…
- Trial name
- NCT01106651
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s)
- Where
- 86 sites in United States, Australia and 15 more
- Volunteers
- 716 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.